This study will investigate the effects of a new diabetes medication on appetite hormones and weight.
The oral medication, known as Empagliflozin (Jardiance™), is licensed for use in the UK as a diabetes treatment and has been shown to improve diabetes control and reduce weight effectively by increasing the amount of glucose (or sugar) in the urine. However, the amount of weight loss seen in people that take this particular drug is less than we would expect given the amount of calories that are lost as glucose in their urine. We think that this might be due to how Empagliflozin (Jardiance™) affects appetite.
The SEESAW study will compare a number of different appetite hormones and weight changes in participants who are given Empagliflozin (Jardiance™) compared to participants who are given a dummy drug (known as a ‘placebo’).
The study will also investigate the effect of being on a low calorie diet in addition to taking these drugs.